Eribulin (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eribulin" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

19nih.gov

4^th place

7^th place

12doi.org

2^nd place

5fda.gov

447^th place

625^th place

3clinicaltrials.gov

5,225^th place

7,218^th place

1hc-sc.gc.ca

low place

6,842^nd place

clinicaltrials.gov

doi.org

Yu, Yanke; Desjardins, Christopher; Saxton, Phil; Lai, George; Schuck, Edgar; Wong, Y. Nancy (2013). "Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice". International Journal of Pharmaceutics. Quyển 443 số 1–2. tr. 9–16. doi:10.1016/j.ijpharm.2013.01.010. PMID 23313921.
Hirata, Y; Uemura, D (1986). "Halichondrins - antitumor polyether macrolides from a marine sponge". Pure and Applied Chemistry. Quyển 58 số 5. tr. 701–710. doi:10.1351/pac198658050701.
Jordan, M. A; Kamath, K; Manna, T; Okouneva, T; Miller, H. P; Davis, C; Littlefield, B. A; Wilson, L (2005). "The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth". Molecular Cancer Therapeutics. Quyển 4 số 7. tr. 1086–95. doi:10.1158/1535-7163.MCT-04-0345. PMID 16020666.
Okouneva, T; Azarenko, O; Wilson, L; Littlefield, B. A; Jordan, M. A (2008). "Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase". Molecular Cancer Therapeutics. Quyển 7 số 7. tr. 2003–11. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith, Jennifer A; Wilson, Leslie; Azarenko, Olga; Zhu, Xiaojie; Lewis, Bryan M; Littlefield, Bruce A; Jordan, Mary Ann (2010). "Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability". Biochemistry. Quyển 49 số 6. tr. 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Wilson, Leslie; Lopus, Manu; Miller, Herbert P; Azarenko, Olga; Riffle, Stephen; Smith, Jennifer A; Jordan, Mary Ann (2015). "Effects of Eribulin on Microtubule Binding and Dynamic Instability Are Strengthened in the Absence of the βIII Tubulin Isotype". Biochemistry. Quyển 54 số 42. tr. 6482–9. doi:10.1021/acs.biochem.5b00745. PMID 26435331.
Kuznetsov, Galina; Towle, Murray J; Cheng, Hongsheng; Kawamura, Takanori; Tendyke, Karen; Liu, Diana; Kishi, Yoshito; Yu, Melvin J; Littlefield, Bruce A (2004). "Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389". Cancer Research. Quyển 64 số 16. tr. 5760–6. doi:10.1158/0008-5472.CAN-04-1169. PMID 15313917.
Towle, M. J; Salvato, K. A; Wels, B. F; Aalfs, K. K; Zheng, W; Seletsky, B. M; Zhu, X; Lewis, B. M; Kishi, Y (2010). "Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for in vivo Efficacy under Intermittent Dosing Conditions". Cancer Research. Quyển 71 số 2. tr. 496–505. doi:10.1158/0008-5472.CAN-10-1874. PMID 21127197.
Funahashi, Yasuhiro; Okamoto, Kiyoshi; Adachi, Yusuke; Semba, Taro; Uesugi, Mai; Ozawa, Yoichi; Tohyama, Osamu; Uehara, Taisuke; Kimura, Takayuki (2014). "Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models". Cancer Science. Quyển 105 số 10. tr. 1334–42. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida, T; Ozawa, Y; Kimura, T; Sato, Y; Kuznetsov, G; Xu, S; Uesugi, M; Agoulnik, S; Taylor, N (2014). "Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states". British Journal of Cancer. Quyển 110 số 6. tr. 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ, Weissleder R (2014). "Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin". Science Translational Medicine. Quyển 6 số 261. tr. 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.
Kim, Dae-Shik; Dong, Cheng-Guo; Kim, Joseph T; Guo, Haibing; Huang, Jian; Tiseni, Paolo S; Kishi, Yoshito (2009). "New Syntheses of E7389 C14−C35 and Halichondrin C14−C38 Building Blocks: Double-Inversion Approach". Journal of the American Chemical Society. Quyển 131 số 43. tr. 15636–41. doi:10.1021/ja9058475. PMID 19807076.

fda.gov

"FDA approves new treatment option for late-stage breast cancer" (Thông cáo báo chí). USFDA. ngày 15 tháng 11 năm 2010. Truy cập ngày 15 tháng 11 năm 2010.
https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm544019.pdf^{[cần chú thích đầy đủ]}
https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/ucm447307.pdf^{[cần chú thích đầy đủ]}
FDA approves first drug to show survival benefit in liposarcoma. Jan 2016

accessdata.fda.gov

https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=201532&Appl_type=N^{[cần chú thích đầy đủ]}

hc-sc.gc.ca

Notice of Decision for HALAVEN^{[liên kết hỏng]}

nih.gov

pubmed.ncbi.nlm.nih.gov

Yu, Yanke; Desjardins, Christopher; Saxton, Phil; Lai, George; Schuck, Edgar; Wong, Y. Nancy (2013). "Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice". International Journal of Pharmaceutics. Quyển 443 số 1–2. tr. 9–16. doi:10.1016/j.ijpharm.2013.01.010. PMID 23313921.
Towle, M. J; Salvato, K. A; Budrow, J; Wels, B. F; Kuznetsov, G; Aalfs, K. K; Welsh, S; Zheng, W; Seletsky, B. M (2001). "In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B". Cancer Research. Quyển 61 số 3. tr. 1013–21. PMID 11221827.
Bai, R. L; Paull, K. D; Herald, C. L; Malspeis, L; Pettit, G. R; Hamel, E (1991). "Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data". The Journal of Biological Chemistry. Quyển 266 số 24. tr. 15882–9. PMID 1874739.
Jordan, M. A; Kamath, K; Manna, T; Okouneva, T; Miller, H. P; Davis, C; Littlefield, B. A; Wilson, L (2005). "The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth". Molecular Cancer Therapeutics. Quyển 4 số 7. tr. 1086–95. doi:10.1158/1535-7163.MCT-04-0345. PMID 16020666.
Okouneva, T; Azarenko, O; Wilson, L; Littlefield, B. A; Jordan, M. A (2008). "Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase". Molecular Cancer Therapeutics. Quyển 7 số 7. tr. 2003–11. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith, Jennifer A; Wilson, Leslie; Azarenko, Olga; Zhu, Xiaojie; Lewis, Bryan M; Littlefield, Bruce A; Jordan, Mary Ann (2010). "Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability". Biochemistry. Quyển 49 số 6. tr. 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Wilson, Leslie; Lopus, Manu; Miller, Herbert P; Azarenko, Olga; Riffle, Stephen; Smith, Jennifer A; Jordan, Mary Ann (2015). "Effects of Eribulin on Microtubule Binding and Dynamic Instability Are Strengthened in the Absence of the βIII Tubulin Isotype". Biochemistry. Quyển 54 số 42. tr. 6482–9. doi:10.1021/acs.biochem.5b00745. PMID 26435331.
Kuznetsov, Galina; Towle, Murray J; Cheng, Hongsheng; Kawamura, Takanori; Tendyke, Karen; Liu, Diana; Kishi, Yoshito; Yu, Melvin J; Littlefield, Bruce A (2004). "Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389". Cancer Research. Quyển 64 số 16. tr. 5760–6. doi:10.1158/0008-5472.CAN-04-1169. PMID 15313917.
Towle, M. J; Salvato, K. A; Wels, B. F; Aalfs, K. K; Zheng, W; Seletsky, B. M; Zhu, X; Lewis, B. M; Kishi, Y (2010). "Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for in vivo Efficacy under Intermittent Dosing Conditions". Cancer Research. Quyển 71 số 2. tr. 496–505. doi:10.1158/0008-5472.CAN-10-1874. PMID 21127197.
Funahashi, Yasuhiro; Okamoto, Kiyoshi; Adachi, Yusuke; Semba, Taro; Uesugi, Mai; Ozawa, Yoichi; Tohyama, Osamu; Uehara, Taisuke; Kimura, Takayuki (2014). "Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models". Cancer Science. Quyển 105 số 10. tr. 1334–42. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida, T; Ozawa, Y; Kimura, T; Sato, Y; Kuznetsov, G; Xu, S; Uesugi, M; Agoulnik, S; Taylor, N (2014). "Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states". British Journal of Cancer. Quyển 110 số 6. tr. 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Kawano, S; Asano, M; Adachi, Y; Matsui, J (2016). "Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma". Anticancer Research. Quyển 36 số 4. tr. 1553–61. PMID 27069131.
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ, Weissleder R (2014). "Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin". Science Translational Medicine. Quyển 6 số 261. tr. 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.
Kim, Dae-Shik; Dong, Cheng-Guo; Kim, Joseph T; Guo, Haibing; Huang, Jian; Tiseni, Paolo S; Kishi, Yoshito (2009). "New Syntheses of E7389 C14−C35 and Halichondrin C14−C38 Building Blocks: Double-Inversion Approach". Journal of the American Chemical Society. Quyển 131 số 43. tr. 15636–41. doi:10.1021/ja9058475. PMID 19807076.

ncbi.nlm.nih.gov

Okouneva, T; Azarenko, O; Wilson, L; Littlefield, B. A; Jordan, M. A (2008). "Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase". Molecular Cancer Therapeutics. Quyển 7 số 7. tr. 2003–11. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith, Jennifer A; Wilson, Leslie; Azarenko, Olga; Zhu, Xiaojie; Lewis, Bryan M; Littlefield, Bruce A; Jordan, Mary Ann (2010). "Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability". Biochemistry. Quyển 49 số 6. tr. 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Funahashi, Yasuhiro; Okamoto, Kiyoshi; Adachi, Yusuke; Semba, Taro; Uesugi, Mai; Ozawa, Yoichi; Tohyama, Osamu; Uehara, Taisuke; Kimura, Takayuki (2014). "Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models". Cancer Science. Quyển 105 số 10. tr. 1334–42. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida, T; Ozawa, Y; Kimura, T; Sato, Y; Kuznetsov, G; Xu, S; Uesugi, M; Agoulnik, S; Taylor, N (2014). "Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states". British Journal of Cancer. Quyển 110 số 6. tr. 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ, Weissleder R (2014). "Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin". Science Translational Medicine. Quyển 6 số 261. tr. 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.